Equities Analysts Offer Predictions for EHC Q1 Earnings

Encompass Health Co. (NYSE:EHC) – Equities research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of Encompass Health in a report released on Tuesday, October 29th. William Blair analyst J. Haase now expects that the company will post earnings of $1.29 per share for the quarter, down from their prior forecast of $1.32. The consensus estimate for Encompass Health’s current full-year earnings is $4.18 per share. William Blair also issued estimates for Encompass Health’s Q2 2025 earnings at $1.24 EPS and Q3 2025 earnings at $1.26 EPS.

EHC has been the topic of a number of other reports. Truist Financial restated a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research note on Wednesday. Royal Bank of Canada boosted their price objective on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday. KeyCorp boosted their price objective on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday. UBS Group boosted their price objective on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Barclays boosted their price objective on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $107.11.

Encompass Health Trading Down 1.9 %

NYSE EHC opened at $99.42 on Thursday. The stock has a market capitalization of $10.00 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 1.45 and a beta of 0.88. Encompass Health has a one year low of $61.08 and a one year high of $102.36. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.35 and a quick ratio of 1.35. The business’s fifty day moving average is $94.33 and its 200-day moving average is $88.69.

Encompass Health (NYSE:EHC) last released its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.86 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Encompass Health by 1.7% during the first quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company’s stock worth $839,520,000 after purchasing an additional 169,113 shares in the last quarter. TD Asset Management Inc boosted its stake in Encompass Health by 16.0% in the first quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock worth $188,586,000 after buying an additional 314,488 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Encompass Health by 1.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,819,345 shares of the company’s stock worth $156,083,000 after buying an additional 22,311 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in Encompass Health by 14.2% in the first quarter. Epoch Investment Partners Inc. now owns 1,598,042 shares of the company’s stock worth $131,966,000 after buying an additional 198,701 shares in the last quarter. Finally, 8 Knots Management LLC boosted its stake in Encompass Health by 14.0% in the first quarter. 8 Knots Management LLC now owns 1,288,815 shares of the company’s stock worth $106,430,000 after buying an additional 158,356 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Transactions at Encompass Health

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares of the company’s stock, valued at approximately $11,761,839.18. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by insiders.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s dividend payout ratio is presently 16.43%.

Encompass Health announced that its Board of Directors has initiated a stock buyback program on Wednesday, July 24th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to buy up to 5.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.